No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Immunotherapy has improved survival in stage IV non-small cell lung cancer (NSCLC); however, primary and acquired resistance remain common and the underlying mechanisms are incompletely understood. Progress has been limited by difficulty obtaining sufficient, high-quality tumour tissue in advanced disease . Linear endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) offers minimally invasive tumour sampling and may provide material suitable for whole exome sequencing (WES). We evaluated the feasibility of WES from EBUS-TBNA specimens and explored genomic correlates of immunotherapy response.
Patients undergoing EBUS for suspected lung cancer were prospectively recruited through the TRACKER lung cancer biobank (2021-2025). EGFR- or ROS1- positive cases were excluded. Immunotherapy responders were defined as patients surviving ≥6 weeks and demonstrating radiological response after ≥6 months of chemoimmunotherapy. WES was performed using standard bioinformatic pipelines to identify somatic single nucleotide variants, small insertions/deletions, tumour mutational burden (TMB), and copy number alterations (CNAs). Genomic features were compared between responders and non-responders.
Eighteen patients (21 EBUS-TBNA samples) were included ((mean age 66 years (range 47-81); 39% female). Nine were classified as responders, eight non-responders, and one had pending outcome data. WES was successful in all analysed samples.
Non-responders demonstrated a greater overall copy number burden, with a higher fraction of the genome affected by CNAs, particularly deletions. TMB was significantly higher in non-responders than responders (12.6 vs 5.6 mutations/Mb, p=0.0018). Distinct gene-level mutational patterns were observed between groups, though interpretation is limited by cohort size.
In this pilot cohort of advanced NSCLC, WES from EBUS-TBNA specimens was feasible and generated high-quality genomic data. Differences in copy number burden and mutational profiles between responders and non-responders warrant validation in larger studies to clarify genomic determinants of immunotherapy resistance.